Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OBIO vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OBIO Captures Overall Composite Edge (41.1 SELL vs 58.2 HOLD), While BHST Leads 5–1 on Growth & Valuation Pillars

OBIO Overall Winner 6-Pillar Tally: OBIO 1 – 5 BHST Matrix Metrics: OBIO 2 – 6 BHST

As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY).
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs BHST
OBIO NASDAQ Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.18β · 88% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $6.19 · SMA50: $6.01
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (OBIO 1 – 5 BHST)

Columns: Metric · OBIO · BHST
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.9x 0.7x
2. Growth & Scale BHST
Revenue Growth (YoY) -89.4% +3.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M $35M
Market Cap $550.9M $29.9M
3. Profitability & Quality BHST
Gross Margin 99.6% 59.0%
Operating Margin -195.4% -18.0%
Net Profit Margin -182.5% -31.2%
Return on Equity (ROE) -182.3% -142.5%
4. Balance Sheet & Cash Flow BHST
Cash Generation (TTM) -$64M -$9.4M
Cash Flow Margin N/A -26.6%
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 78.2% (21st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity N/A 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (2) vs BHST (6)
Institutional Metric OBIO BHST Criterion Row Edge
Market Capitalization
Scale
$550.9M $29.9M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-89.4% +3.8% Higher Growth BHST
Operating Margin (TTM)
Profitability
-195.4% -18.0% Higher Margin BHST
Net Profit Margin
Profitability
-182.5% -31.2% Higher Margin BHST
Return on Equity (ROE)
Capital Efficiency
-182.3% -142.5% Higher ROE BHST
52-Week Range Position
Momentum
72% ($3–$8) 6% ($1–$7) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.18β · 88% Vol 0.25β · 86% Vol Lower Realized Risk BHST
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 58.2 / 100 (HOLD) Higher Composite BHST
Trailing 12M Revenue (USD)
Operating Scale
$31M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.9x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +42.91 pp
OBIO: +20.29% · BHST: -22.62%
3M Horizon OBIO +57.55 pp
OBIO: +20.96% · BHST: -36.59%
6M Horizon OBIO +128.39 pp
OBIO: +62.07% · BHST: -66.32%
1Y Horizon OBIO +120.6 pp
OBIO: +41.2% · BHST: -79.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OBIO Revenue BHST Revenue OBIO Op. Margin BHST Op. Margin Margin Leader
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M $10M -1866.2% -78.6% BHST
FY2024 $0M $30M -2437.5% -27.7% BHST
FY2025 $30M $30M -154.7% -16.2% BHST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO CONSOLIDATION
36d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY). Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BHST leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), OBIO cumulative revenue shifted N/A while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

BHST screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.